Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 310

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 310
---
Increase (Decrease) from 2024 to 2025Nine Months EndedSeptember 30,Increase (Decrease) from 2024 to 2025Program Expenses:20252024$%20252024$%Shingles$9,903 $5,141 $4,762 93%$22,587 $12,289 $10,298 84 %Plague (1)2,187 503 1,684 335 %4,872 3,580 1,292 36 %HEPLISAV-B and CpG 1018 adjuvant development1,146 1,093 53 5%4,368 4,091 277 7 %Tdap— 1,119 (1,119)(100)%127 3,805 (3,678)(97)%Other2,757 2,741 16 1%13,088 8,411 4,677 56%Other research and development expenses:Facility costs641 671 (30)(4%)1,770 2,024 (254)(13%)Non-cash stock-based compensation2,482 3,135 (653)(21%)8,300 8,681 (381)(4%)Total research and development$19,116 $14,403 $4,713 33%$55,112 $42,881 $12,231 29%

(1)In September 2021, we entered into an agreement with the DoD for the development of a recombinant plague vaccine utilizing CpG 1018 adjuvant. Under the agreement, we conducted a Phase 2 clinical trial and studies combining our CpG 1018 adjuvant with the DoD's rF1V vaccine. We are being fully reimbursed by the DoD for the costs of this study, which is recorded in other revenue in our condensed consolidated statements of operations. 

Research and development expenses increased by $4.7 million and $12.2 million for the three and nine months ended September 30, 2025, respectively, compared to the same periods in 2024. The increase in research and development expenses was primarily driven by higher costs associated with our shingles program due to the ongoing Phase 1/2 clinical trial, the progression of our plague vaccine candidate in a Phase 2 clinical study, increased investment in the initiation